IL271470B2 - Plasminogen therapy in conditions associated with pai–1 overexpression - Google Patents

Plasminogen therapy in conditions associated with pai–1 overexpression

Info

Publication number
IL271470B2
IL271470B2 IL271470A IL27147019A IL271470B2 IL 271470 B2 IL271470 B2 IL 271470B2 IL 271470 A IL271470 A IL 271470A IL 27147019 A IL27147019 A IL 27147019A IL 271470 B2 IL271470 B2 IL 271470B2
Authority
IL
Israel
Prior art keywords
plasminogen
pai
disease
use according
subject
Prior art date
Application number
IL271470A
Other languages
English (en)
Hebrew (he)
Other versions
IL271470A (en
IL271470B1 (en
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of IL271470A publication Critical patent/IL271470A/en
Publication of IL271470B1 publication Critical patent/IL271470B1/en
Publication of IL271470B2 publication Critical patent/IL271470B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL271470A 2017-06-23 2018-06-22 Plasminogen therapy in conditions associated with pai–1 overexpression IL271470B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 PLASMINOGEN TREATMENT OF AFFECTIONS ASSOCIATED WITH OVEREXPRESSION OF PAI-1

Publications (3)

Publication Number Publication Date
IL271470A IL271470A (en) 2020-01-30
IL271470B1 IL271470B1 (en) 2025-03-01
IL271470B2 true IL271470B2 (en) 2025-07-01

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271470A IL271470B2 (en) 2017-06-23 2018-06-22 Plasminogen therapy in conditions associated with pai–1 overexpression

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI787732B (zh) * 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
CN115666625A (zh) * 2020-03-24 2023-01-31 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
US20230173039A1 (en) * 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
KR20220158036A (ko) * 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US20160200831A1 (en) * 2013-08-13 2016-07-14 Sanofi Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
CA3047170A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
JP7168990B2 (ja) * 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US20160200831A1 (en) * 2013-08-13 2016-07-14 Sanofi Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TROY LAUREN K., AND TAMERA J. CORTE:, THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS: LESSONS FROM POOLED DATA ANALYSES, 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
IL271470A (en) 2020-01-30
WO2018234861A1 (en) 2018-12-27
EP3641888A4 (en) 2021-03-10
AU2018287316A1 (en) 2020-02-06
DK3641888T3 (da) 2024-01-02
EP3641888B1 (en) 2023-10-11
NZ760921A (en) 2026-01-30
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
US20210330761A1 (en) 2021-10-28
CN110831668A (zh) 2020-02-21
AU2018287316B2 (en) 2024-09-19
KR20200019217A (ko) 2020-02-21
EP3641888A1 (en) 2020-04-29
ZA202000280B (en) 2021-08-25
CN110831668B (zh) 2024-04-12
MY203136A (en) 2024-06-10
TW201904990A (zh) 2019-02-01
CA3068153A1 (en) 2018-12-27
SG11201912813SA (en) 2020-01-30
IL271470B1 (en) 2025-03-01
RU2020100080A3 (enExample) 2021-11-02
RU2020100080A (ru) 2021-07-23
ES2965937T3 (es) 2024-04-17
MX2019015741A (es) 2020-11-11
JP2020524689A (ja) 2020-08-20
CL2019003789A1 (es) 2020-07-10
TWI868051B (zh) 2025-01-01
BR112019027229A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
US11826404B2 (en) Plasminogen treatment of conditions associated with PAI-1 overexpression
Peng et al. Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke
McCarthy et al. Reconstitution of autophagy ameliorates vascular function and arterial stiffening in spontaneously hypertensive rats
WO2015070619A1 (zh) 鸢尾素在制备预防心肌缺血再灌注损伤的药物中的应用
JP2009531036A (ja) Ｖｅｇｆ受容体融合タンパク質およびそれらの使用
WO2008091692A2 (en) Methods of diagnosing, treating, and preventing increased vascular permeability
Zeng et al. Paeoniflorin of Paeonia lactiflora prevents renal interstitial fibrosis induced by unilateral ureteral obstruction in mice
Zhu et al. MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity
CA3152346A1 (en) Methods of treatment for modifying hemodynamics
Tang et al. Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a
Cavaglia et al. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs
KR20130058669A (ko) 릴랙신을 사용한 아쿠아포린의 조절
CN103038253A (zh) 作为用来稳定生物屏障的活性剂的肽
Shi et al. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger
Earle et al. Ubiquitin reduces fluid shifts after traumatic brain injury
EP4471154A1 (en) Use of kinin or derivative thereof in treating vci, psci, or csvd
Su et al. Overexpression of Corin ameliorates kidney fibrosis through Inhibition of Wnt/β-Catenin signaling in mice
CN110511266B (zh) 一种小分子多肽及其用途
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
US10272133B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US20200000939A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Jitsuiki et al. A case of blue rubber bleb nevus syndrome with Kasabach-Merritt syndrome and heart failure
WO2019048898A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
Tesoro et al. TITTLE: Cardioprotective Effect of New NIL10 Nanoparticles Through IL10 Receptor/STAT3 Activation in Mice and Pigs Subjected Acute Myocardial Infarction